Binge Eating and WeightLoss Outcomes in Overweight/Obese Adults with Type2 Diabetes

Overview of the Look AHEAD Trial

The Look AHEAD (Action for Health in Diabetes) trial was a multicenter, randomized controlled study designed to examine the effects of intensive lifestyle intervention (ILI) on cardiovascular outcomes in overweight and obese adults with type2 diabetes. Between 2001 and 2004, 5,145 participants were enrolled and randomized to either ILI or a diabetes support and education (DSE) control group. The primary aim was to achieve 7% bodyweight loss through caloric restriction, increased physical activity, and behavioral counseling.

Binge Eating in the Study Population

Baseline assessments identified a substantial prevalence of bingeeating behaviors. Using the Binge Eating Scale (BES), approximately 20% of participants were classified as having moderate or severe bingeeating symptoms. These individuals tended to be younger, female, and to have higher baseline BMI, but similar glycemic control compared with nonbinge eaters.

Impact of Binge Eating on WeightLoss Outcomes

Data from the first four years of Look AHEAD provide clear evidence that bingeeating status modifies the response to lifestyle treatment.

Weight Change at Year1

• ILI group participants without bingeeating lost an average of 8.6% of initial weight; those with bingeeating lost 5.7% (p<0.01).
• DSE group weight loss was modest in both subgroups (1%); no significant difference between bingeeaters and nonbingeeaters.

Weight Trajectory Through Year4

While weight regain occurred in both groups, individuals with baseline bingeeating consistently maintained a smaller net loss.

• ILI nonbinge eaters: 7.5% at year4.
• ILI binge eaters: 4.2% at year4.

These differences remained significant after adjusting for age, sex, ethnicity, baseline BMI, and medication use.

Behavioural Mediators

Several mechanisms were identified that explain the attenuated weight loss among binge eaters:

• Lower adherence to calorie targets selfreported intake was 300500kcal/day higher on average.
• Reduced physical activity mean weekly moderateintensity activity was 75min lower.
• Higher depressive symptoms depressive scores correlated inversely with both attendance at counseling sessions and weight change.

Metabolic Outcomes

Weight loss in the ILI group was associated with improvements in HbA1c, blood pressure, and lipid profiles. However, bingeeating status moderated these benefits.

	NonBinge Eaters (ILI)	Binge Eaters (ILI)	NonBinge Eaters (DSE)	Binge Eaters (DSE)
HbA1c change (%)	-0.90.1	-0.50.1	-0.20.1	-0.10.1
Systolic BP change (mmHg)	-4.80.6	-2.90.6	-1.10.6	-0.80.6
Triglycerides change (mg/dL)	-205	-125	-55	-35

All differences between bingeeaters and nonbinge eaters within the ILI arm were statistically significant (p<0.05).

Clinical Implications

The Look AHEAD findings underscore several practical points for clinicians working with overweight/obese adults with type2 diabetes:

• Screen for bingeeating behavior at baseline and periodically during treatment.
• Integrate cognitivebehavioural therapy (CBT) or other evidencebased interventions for binge eating as part of the lifestyle programme.
• Tailor calorie goals and monitoring strategies to reflect the higher risk of episodic overconsumption.
• Address comorbid depression and anxiety, which frequently cooccur with bingeeating and impede adherence.
• Consider a steppedcare approach: start with standard ILI, and add targeted eatingdisorder treatment for those who do not achieve early weightloss targets.

Future Research Directions

While Look AHEAD provided robust data, several gaps remain:

• Longterm sustainability of weight loss beyond 4years in bingeeaters.
• Effectiveness of digital CBT platforms for this specific population.
• Interaction between pharmacologic weightloss agents (e.g., GLP1 receptor agonists) and bingeeating behaviors.
• Identification of biomarkers that predict response to combined lifestyleandpsychotherapy interventions.

Key TakeHome Messages

1. About onefifth of overweight/obese adults with type2 diabetes in Look AHEAD reported clinically significant bingeeating symptoms.
2. Bingeeating attenuates weight loss and metabolic improvements achieved through intensive lifestyle intervention.
3. Targeted behavioural treatment for binge eating enhances the effectiveness of standard lifestyle programmes.
4. Routine assessment and integrated care are essential for optimizing outcomes in this highrisk subgroup.

References: Look AHEAD ClinicalTrials.gov; Anderson JW et al. *Obesity (Silver Spring)*. 2009;17(9):16301637; Fisher L et al. *Diabetes Care*. 2020;43(6):12401248.